A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

NCT06406465 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

NIH

Sponsor class

Conditions

Carcinoma, Neuroendocrine
Tumor, Neuroendocrine
Tumors, Neuroendocrine
Neuroendocrine; Carcinoma
Small Cell; Receptors

Interventions

DRUG: Belinostat
DRUG: Cisplatin
DRUG: Etoposide

Sponsor

National Cancer Institute (NCI)